ACCREDITED PROVIDERS
Provided by the American Association for the Study of Liver Diseases and The France Foundation.
Accreditation Statement - The American Association for the Study of Liver Diseases
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION - The American Association for the Study of Liver Diseases
The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MAINTENANCE OF CERTIFICATION - The American Association for the Study of Liver Diseases
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Accreditation Statement - The France Foundation
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
NURSES - The France Foundation
The France Foundation designates this activity for 1.0 contact hour of nursing continuing professional development credit.
PHYSICIAN ASSISTANTS - The France Foundation
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 30, 2027. PAs should only claim credit commensurate with the extent of their participation.
DISCLOSURE POLICY - The American Association for the Study of Liver Diseases
This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education. As an accredited provider, AASLD must collect information from all planners, faculty, and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.
The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE POLICY - The France Foundation
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers, and presenters comply with the ACCME Standards Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships are present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org).
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
Faculty
Marc Ghany, MD, MHSc, FAASLD
Grant/Research Support: NIDDK
Robert Gish, MD, FAASLD
Scientific Consultant/Advisor: AbbVie, AstraZeneca, BlueJay (Mirum), Brii Bio, EIT Pharma, Genlantis, GLG, Gilead, GSK, HHHbio, Helio, HepQuant, Ipsen, Madrigal, Mirum, Precision BioSciences, Prodigy, Quest, Topography Health, Tune Therapeutics, Intercept, Janssen, JBS Science, Kinnate Bio, Merck, Pfizer, Seres Therapeutics, Venatorx, Virion, Fujifilm/Wako
Grant/Research Support: Gilead
Speakers Bureau: Gilead Sciences Inc., HepQuant, AlfaSigma/Intercept, Ipsen Biopharmaceuticals, Madrigal, Mallinckrodt, Mirum
Data Safety Monitoring Board: Syneos Health/Bausch, Takeda, LISCure
Equity Consultant: Genlantis, HepQuant, HepaTx, Virion
Sarah Yuan, NP
Nothing to disclose
David Urick
Nothing to disclose
Mikhail Alper, PA-C
Speaker: Gilead Sciences, Ipsen, Salix, Ardelyx, Johnson & Johnson, Abbvie, Lilly, Phathom, Pfizer, Nestle, AlphaSigma, Madrigal, Regeneron/Sanofi, Castle Biosciences
Advisor: Gilead Sciences, Ipsen, Salix, Abbvie, Pfizer, Johnson & Johnson, Lilly, Novo Nordisk, GSK, Nestle, Zydus, Mirum, Madrigal
The France Foundation Staff
Erika Fox
Nothing to disclose
Amanda Noe
Nothing to disclose
Heather Tarbox, MPH
Nothing to disclose
Melissa Glasner, MSc
Nothing to disclose
Patrick Harty, PhD
Nothing to disclose
Sean Conlan, BA, BS
Nothing to disclose
Boris Rozenfeld, MD
Nothing to disclose
AASLD Staff:
Roxanne Dobbs
Nothing to disclose
Steve Folstein, MFA, M.Ed.
Nothing to disclose
DISCLOSURE OF UNLABELED USE
Faculty for this educational activity are required to disclose when a therapy or procedure being discussed is off-label, unlabeled, experimental, or investigational and to note any limitations of the data presented (eg, preliminary findings, ongoing research, or expert opinion).
Some faculty may discuss uses of pharmaceutical agents or devices that are not included in US Food and Drug Administration–approved labeling. These discussions are provided solely for educational purposes and should not be construed as a recommendation for any particular use. Learners are encouraged to review full prescribing information for products discussed.
DISCLAIMER
This activity is intended for health care professionals for educational purposes only. The content reflects information available at the time of development and may not represent the most current evidence, regulatory status, or prescribing information. Participants should consult current package inserts, clinical guidelines, and institutional policies before prescribing medications or making clinical decisions.
This activity has been planned and implemented in compliance with applicable accreditation standards to ensure that content is fair, balanced, evidence-based, and free of commercial bias.
AI-Assisted Content
This educational activity includes content generated with the support of artificial intelligence (AI)/chatbot tools and reviewed by subject-matter experts. It is intended solely for educational purposes and does not provide medical advice, diagnosis, or treatment recommendations.
AI‑supported content may contain errors or omissions, and it should not be relied upon as a substitute for the independent clinical judgment of qualified health care professionals or for patient‑specific decision making.
Learners are responsible for critically evaluating all information and applying it in accordance with professional standards, current evidence, regulatory requirements, and the laws of their practicing jurisdiction.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an independent medical educational grant from GSK.
CONTACT INFORMATION
If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.